Search results
Results from the WOW.Com Content Network
Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter. [1]
1942 – gramicidin S, the first peptide antibiotic; 1942 – sulfadimidine; 1943 – sulfamerazine; 1944 – streptomycin, the first aminoglycoside [2] 1947 – sulfadiazine; 1948 – chlortetracycline, the first tetracycline; 1949 – chloramphenicol, the first amphenicol [2] 1949 – neomycin; 1950 – oxytetracycline; 1950 – penicillin G ...
Regions of Florida with Cities. Map showing Florida's travel regions, subregions, cities, and major destinations. ... Reverting to most recent version before archival ...
Map of the United States with Florida highlighted Map of Florida's municipalities. Florida is a state located in the Southern United States. There are 267 cities, 123 towns, and 21 villages in the U.S. state of Florida, a total of 411 municipalities. [1] They are distributed across 67 counties, in addition to 66 county governments. [2]
Central Florida seems to be where most of the cases of leprosy in the state are located, based on recent data. Of the 15 cases reported so far this year, most were in Brevard County, in East ...
Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005. [25] In December 2008, the U.S. Food and Drug Administration (FDA) declined to approve oritavancin without additional studies, and an EU application was withdrawn. [citation needed]
Two New York locations took the top spots but five Florida cities were on the list of the top 100 places families wanted to visit this year.
The Antibiotic Development to Advance Patient Treatment (ADAPT) Act was introduced in the U.S. Congress on December 12, 2013 by Representative Phil Gingrey of Georgia and fifty-two cosponsors. Responding to the lack of financial incentives for drug manufacturers to innovate new antibiotics and antifungals and the regulatory barriers to their ...